Last reviewed · How we verify

Anastrozole and goserelin — Competitive Intelligence Brief

Anastrozole and goserelin (Anastrozole and goserelin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase inhibitor and GnRH agonist. Area: Oncology.

phase 2 Aromatase inhibitor and GnRH agonist Aromatase and GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Anastrozole and goserelin (Anastrozole and goserelin) — AstraZeneca. Aromatase inhibitor

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Anastrozole and goserelin TARGET Anastrozole and goserelin AstraZeneca phase 2 Aromatase inhibitor and GnRH agonist Aromatase and GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase inhibitor and GnRH agonist class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anastrozole and goserelin — Competitive Intelligence Brief. https://druglandscape.com/ci/anastrozole-and-goserelin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: